InspireMD (OTC:NSPR) said today that it’s looking for a replacement for CEO Alan Milinazzo as it looks to drill down on the largest markets for its CGuard and MGuard stents, which are designed to help prevent blood clots that can cause stroke.
Milinazzo agreed to stay on until either a replacement is found or June 30, whichever comes 1st. The new CEO will be hired to grow sales in Europe and improve the balance sheet, InspireMD said.
The Boston-based company said also said it tapped as vice chairman biotech legend Isaac Blech, the founder of Celgene (NSDQ:CELG), ICOS Corp., Pathogenesis, Nova Pharmaceutical and Genetic Systems.
“We are very pleased to welcome Isaac Blech as vice chairman of InspireMD. Isaac’s experience as an industry pioneer, taking new technologies from development to commercialization, will be instrumental as we continue with our efforts to introduce and develop markets that leverage our proprietary MicroNet technology. We also welcome Isaac’s deep relationships and extensive professional network across multiple fields – including the financial, pharmaceutical, biotechnology and medical device communities – supporting our active efforts to validate our technology and capabilities,” chairman Sol Barer said in prepared rernarks. “Finally, we thank Alan Milinazzo for effectively taking the Company through its challenging transition. We are now well underway as we execute on our carotid and neurovascular strategy and look forward to announcing a new CEO who will focus the Company’s present efforts towards Europe, the heart of our current commercial activities.”
In a separate regulatory filing, InspireMD said R&D SVP and CTO Eli Bar will step down March 11.
IsoRay replaces CEO Babcock with chairman LaVoy
IsoRay (NYSE:ISR) said it tapped chairman Thomas LaVoy to replace CEO Dwight Babcock effective Feb. 15, giving LaVoy free rein to reshape the company, who currently serves as Chairman of the Board, as CEO, to take office on February 15, 2016.
“I am very excited about the new direction I plan to take this company. I plan on spending significant time in Richland, Wash., at the manufacturing facility. My initial focus will be to locate talented sales representatives and restructure the marketing and sales teams,” LaVoy said in prepared remarks. “The board of directors believes it is now time to focus more on how to increase our revenues, particularly in our core prostate applications.”
HemaFlo Therapeutics names Martino CEO
HemaFlo Therapeutics, which is developing intravenous designed to reduce drag in flowing blood, said it named former Ambit Biosciences CEO Michael Martino to be its new CEO. HemaFlo’s lead product is called NephroFlow and is aimed at treating acute kidney injury.
RefleXion Medical names Intuitive Surgical founder Moll to board
RefleXion Medical said it named Dr. Frederic Moll, a co-founder of Intuitive Surgical (NSDQ:ISRG), to its board of directors.